STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after surgery may keep lung cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
Targeted pill may keep EGFR lung cancer from returning after surgery
Disease control OngoingThis phase 3 trial tests whether taking erlotinib (Tarceva) after surgery helps people with EGFR-mutant non-small cell lung cancer live longer and stay cancer-free longer. About 390 patients who had their lung cancer completely removed are randomly assigned to receive erlotinib p…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects.…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail for tough lung cancer shows promise in small trial
Disease control OngoingThis phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Massive lung cancer study aims to match patients with targeted therapies
Knowledge-focused OngoingThis large study (ALCHEMIST) is screening over 8,000 people with early-stage non-small cell lung cancer to analyze the genes in their tumors. The goal is to identify genetic changes that could help doctors choose the best treatments, such as targeted therapies. Participants provi…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 08:00 UTC